Familial Atherosclerosis Treatment Study (FATS)

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

Familial Atherosclerosis Treatment Study (FATS) On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Familial Atherosclerosis Treatment Study (FATS)

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Familial Atherosclerosis Treatment Study (FATS)

CDC on Familial Atherosclerosis Treatment Study (FATS)

Familial Atherosclerosis Treatment Study (FATS) in the news

Blogs on Familial Atherosclerosis Treatment Study (FATS)

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for Familial Atherosclerosis Treatment Study (FATS)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Familial Atherosclerosis Treatment Study

Objective

The objective of this study is to compare the effects of two intensive lipid altering therapies in men with familial combined hyperlipidemia as assessed by arteriography.

National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Timeline
Start Date January 1984
End Date August 1989
Status Completed

The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00000512.

Study Description

Study Description
Study Type Interventional
Study Phase Phase 3
Study Design
Allocation Randomized
Endpoint Efficacy Study
Interventional Model Parallel Assignment
Masking Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Study Details
Primary Purpose Treatment
Condition Cardiovascular Diseases, coronary arteriosclerosis, coronary disease, heart diseases, myocardial ischemia
Intervention Drug: lovastatin
Drug: colestipol
Drug: niacin
Study Arms Experimental: Niacin—Colestipol Group
Experimental: Lovastatin—Colestipol Group
Placebo Comparator: Conventional-Therapy Group
Population Size 146

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00000512.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Outcomes

Primary Outcomes

Change in the mean severity of proximal stenosis

Publications

Conclusion

Both the intensive lipid lowering therapies were equally effective. Both reduced the frequency of progression of coronary lesions (21% and 25% versus 46% in the control group), increased the frequency of regression (32% and 39% versus 11%), and reduced the incidence of cardiovascular events in men with coronary artery disease who were at high risk for cardiovascular events.[1][2][3][4][5][6][7]

References

  1. Brown G, Albers JJ, Fisher LD; et al. (1990). "Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B". N. Engl. J. Med. 323 (19): 1289–98. doi:10.1056/NEJM199011083231901. PMID 2215615. Unknown parameter |month= ignored (help)
  2. Zhao XQ, Brown BG, Hillger L; et al. (1993). "Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B". Circulation. 88 (6): 2744–53. PMID 8252687. Unknown parameter |month= ignored (help)
  3. Phan BA, Muñoz L, Shadzi P; et al. (2013). "Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study". Am. J. Cardiol. 111 (3): 352–5. doi:10.1016/j.amjcard.2012.09.034. PMID 23168285. Unknown parameter |month= ignored (help)
  4. Stewart BF, Brown BG, Zhao XQ; et al. (1994). "Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol". J. Am. Coll. Cardiol. 23 (4): 899–906. PMID 8106695. Unknown parameter |month= ignored (help)
  5. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ (1995). "Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study". Ann. N. Y. Acad. Sci. 748: 407–17, discussion 417–8. PMID 7695184. Unknown parameter |month= ignored (help)
  6. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ (1995). "Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)". JAMA. 274 (22): 1771–4. PMID 7500507. Unknown parameter |month= ignored (help)
  7. Zambon A, Hokanson JE, Brown BG, Brunzell JD (1999). "Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density". Circulation. 99 (15): 1959–64. PMID 10208998. Unknown parameter |month= ignored (help)